Keys T F
Mayo Clin Proc. 1977 Nov;52(11):680-2.
Sulfonamides, trimethoprim-sulfamethoxazole, nitrofurantoin, and nalidixic acid are excreted in the urine in high concentration and, with the exception of Pseudomonas aeruginosa and Serratia marcescens, are all active in vitro against usual aerobic gram-negative bacteria. They are useful for treatment of uncomplicated lower urinary tract infections in an outpatient setting but are probably not indicated for acute upper tract infections, especially in the hospitalized patient. Trimethoprim-sulfamethoxazole is a very effective combination agent in vitro, has appealing pharmacokinetic properties, and is usually well tolerated by patients. However, it is more expensive than the sulfonamides and is ordinarily not indicated for initial treatment. A sulfonamide is in our view still the agent of first choice, with either nitrofurantoin or nalidixic acid as an alternative if sulfonamides cannot be tolerated.
磺胺类药物、甲氧苄啶-磺胺甲恶唑、呋喃妥因和萘啶酸在尿液中以高浓度排泄,除铜绿假单胞菌和粘质沙雷氏菌外,它们在体外对常见的需氧革兰氏阴性菌均有活性。它们可用于门诊治疗单纯性下尿路感染,但可能不适用于急性上尿路感染,尤其是住院患者。甲氧苄啶-磺胺甲恶唑在体外是一种非常有效的联合用药,具有良好的药代动力学特性,患者通常耐受性良好。然而,它比磺胺类药物更昂贵,通常不用于初始治疗。在我们看来,磺胺类药物仍是首选药物,如果不能耐受磺胺类药物,可选择呋喃妥因或萘啶酸作为替代药物。